(Reuters) -The U.S. Food and Drug Administration has placed a clinical hold on Iovance Biotherapeutics’ lung cancer therapy trial after a patient death, the company said on Wednesday.
Shares of the company were down 26.9% in premarket trading.
The company said that it will pause enrollment in trial studying LN-145 TIL during the hold, while patients who were previously treated with the therapy for non-small cell lung cancer will continue to be monitored.
The company said that it will work with the FDA to safely resume enrollment as soon as possible.
Non-small cell lung cancer is a disease in which cancer cells form in the tissues of the lung.
(Reporting by Christy Santhosh; Editing by Shailesh Kuber)
